A relatively little-known cancer screening company is getting a major vote of confidence from Wall Street, with Jefferies predicting the stock could climb nearly 50% as the company moves toward broader commercialization of its cancer-detection technology.
Jefferies initiated coverage of Freenome (NASDAQ: FRNM) with a Buy rating and a $17 price target, implying approximately 47% upside from Friday’s closing price. The bullish call comes as Freenome prepares to significantly expand commercialization of its cancer-screening services beginning this fall.
Shares jumped more than 7% following the Jefferies call and have gained roughly 12% over the past three months.
Why Jefferies Sees 47% Upside
Jefferies analyst Tycho Peterson believes investors may be underestimating the number of potential catalysts ahead for Freenome.
While broader commercialization is only beginning, Peterson sees several possible sources of additional value, including royalties, milestone payments and expansion into additional cancer indications.
“We see FRNM as uniquely positioned from a development and commercial standpoint, with a multi-year penetration ramp ahead,” Peterson wrote in a note to clients.
That commercialization ramp could be critical. Freenome is developing blood-based cancer screening technology designed to detect cancer at earlier stages, when treatment can potentially be more effective.
The company’s initial focus has been colorectal cancer, but Jefferies believes that could represent only the beginning of the opportunity.
Freenome Could Expand Beyond Colorectal Cancer
One of the biggest pieces of Jefferies’ bullish thesis is Freenome’s potential to expand into other major cancer markets.
Peterson expects the company could eventually broaden its focus from colorectal cancer into lung cancer and other forms of the disease, significantly expanding the addressable market for its screening technology.
That matters because cancer screening is increasingly moving toward less invasive testing methods. Blood-based tests could potentially make screening easier for patients who otherwise avoid or delay traditional procedures.
For investors, successful expansion beyond colorectal cancer could transform Freenome from a company targeting one major screening market into a broader cancer-detection platform.
Jefferies believes that possibility is not yet fully reflected in the stock.
Insurance Coverage Could Be the Next Major Catalyst
Technology alone, however, does not guarantee commercial success in healthcare.
One of the most important factors for Freenome will be whether insurers are willing to pay for its tests.
Jefferies sees encouraging signs on that front.
Peterson pointed to a potential series of reimbursement catalysts following the inclusion of colorectal cancer screening in American Cancer Society guidelines. He also sees the possibility of broader commercial insurance coverage before an anticipated U.S. Preventive Services Task Force guideline review in late 2027 or 2028.
Expanded reimbursement could dramatically improve accessibility. If more insurers cover blood-based colorectal cancer screening, patients would face fewer financial barriers to testing, potentially increasing adoption.
For Freenome, that could mean a substantially larger pool of paying customers just as the company begins expanding commercialization.
A Potential Multi-Year Growth Story
Jefferies’ $17 target isn’t based solely on a short-term product launch.
The firm’s thesis centers on what could become a multi-year adoption cycle as Freenome increases penetration, secures reimbursement and potentially adds new cancer indications.
There are several pieces investors will likely be watching closely:
- The pace of commercialization beginning this fall
- Adoption of Freenome’s colorectal cancer screening services
- Additional insurance reimbursement decisions
- Expansion into lung cancer and other indications
- Future clinical and regulatory milestones
- The company’s ability to translate adoption into sustainable revenue growth
Progress across several of those areas could strengthen Jefferies’ bullish case. Delays in commercialization, reimbursement or clinical development could have the opposite effect.
Wall Street Is Betting on a Much Bigger Opportunity
Freenome remains a relatively under-the-radar name compared with many larger biotechnology and healthcare companies, but Jefferies believes that could change as commercialization accelerates.
The stock has already begun attracting attention. Shares have risen about 12% over the past three months and jumped more than 7% after Jefferies initiated coverage.
With a $17 price target representing roughly 47% upside, Jefferies is effectively betting that investors haven’t fully priced in Freenome’s commercialization opportunity, potential insurance coverage and ability to move beyond colorectal cancer.
The next several quarters could determine whether that optimism is justified.
If Freenome can successfully move its cancer-screening technology into broader commercial use while expanding reimbursement and pursuing additional cancer types, the company could have a considerably larger opportunity ahead than its current profile suggests.
For investors willing to accept the risks that come with an emerging healthcare company, Freenome is now one little-known cancer screening stock worth watching closely.
About Author
